Tharimmune (THAR) reported Monday preclinical data from its expanded pipeline featuring dual-target biologics HS1940 and HS3215, which it says was "positive."
HS1940 is designed to bind to both programmed death-1, or PD-1, and vascular endothelial growth factor, or VEGF, potentially improving treatment outcomes for various cancers. HS3215 targets human epidermal growth factor receptors 2 and 3, or HER2 and HER3, key proteins involved in cancer growth. HS1940 and HS3215 were developed using Tharimmune's antibody engineering platform, EpiClick Technology, the company said.
The company also said it aims to further improve the binding characteristics of HS1940 and present more data at future conferences, with plans to begin investigational new drug, or IND-enabling studies in 2025. Tharimmune also said it is conducting preclinical studies on HS3215 and plans to advance it into clinical trials after IND-enabling studies.
Shares of Tharimmune were down nearly 7% in recent trading.
Price: 1.10, Change: -0.08, Percent Change: -6.86
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.